These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 16625865)

  • 41. Peptide receptor radionuclide therapy for advanced neuroendocrine tumors.
    Bodei L; Cremonesi M; Kidd M; Grana CM; Severi S; Modlin IM; Paganelli G
    Thorac Surg Clin; 2014 Aug; 24(3):333-49. PubMed ID: 25065935
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Is (90)Y-DOTATOC treatment for neuroendocrine tumours safe?
    Cybulla M; Weiner SM; Otte A
    Med Sci Monit; 2002 Apr; 8(4):LE7. PubMed ID: 11951054
    [No Abstract]   [Full Text] [Related]  

  • 43. Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters.
    Ginj M; Hinni K; Tschumi S; Schulz S; Maecke HR
    J Nucl Med; 2005 Dec; 46(12):2097-103. PubMed ID: 16330576
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Peptide receptor radionuclide therapy of neuroendocrine tumours.
    Brabander T; Teunissen JJ; Van Eijck CH; Franssen GJ; Feelders RA; de Herder WW; Kwekkeboom DJ
    Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):103-14. PubMed ID: 26971847
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diagnostic and therapeutic applications of radiolabeled somatostatin analogs: current status in an oncology center.
    Podoloff DA
    Curr Pharm Des; 2002; 8(20):1809-14. PubMed ID: 12171532
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors.
    Kvols LK; Woltering EA
    Anticancer Drugs; 2006 Jul; 17(6):601-8. PubMed ID: 16917205
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Different radioactivity uptake between somatostatin analogues labelled with ¹¹¹In and ⁹⁰/⁸⁸Y in rat kidney.
    Laznicek M; Laznickova A
    Anticancer Res; 2012 Mar; 32(3):815-22. PubMed ID: 22399599
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeted radionuclide therapy for neuroendocrine tumours.
    Lewington VJ
    Endocr Relat Cancer; 2003 Dec; 10(4):497-501. PubMed ID: 14713264
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recent issues on dosimetry and radiobiology for peptide receptor radionuclide therapy.
    Cremonesi M; Ferrari M; Di Dia A; Botta F; De Cicco C; Bodei L; Paganelli G
    Q J Nucl Med Mol Imaging; 2011 Apr; 55(2):155-67. PubMed ID: 21386788
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Application of single-vial ready-for-use formulation of 111In- or 177Lu-labelled somatostatin analogs.
    de Blois E; Chan HS; de Zanger R; Konijnenberg M; Breeman WA
    Appl Radiat Isot; 2014 Feb; 85():28-33. PubMed ID: 24365877
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 68Gallium- and 90Yttrium-/ 177Lutetium: "theranostic twins" for diagnosis and treatment of NETs.
    Werner RA; Bluemel C; Allen-Auerbach MS; Higuchi T; Herrmann K
    Ann Nucl Med; 2015 Jan; 29(1):1-7. PubMed ID: 25139472
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Y90 selective internal radiation therapy and peptide receptor radionuclide therapy for the treatment of metastatic neuroendocrine tumors: combination or not?
    Yilmaz E; Engin MN; Özkan ZG; Kovan B; Büyükkaya F; Poyanli A; Sağlam S; Başaran M; Türkmen C
    Nucl Med Commun; 2020 Dec; 41(12):1242-1249. PubMed ID: 32941405
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New advances in peptide receptor radionuclide therapy.
    de Jong M; Krenning E
    J Nucl Med; 2002 May; 43(5):617-20. PubMed ID: 11994523
    [No Abstract]   [Full Text] [Related]  

  • 54. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide.
    Kwekkeboom DJ; Krenning EP; Scheidhauer K; Lewington V; Lebtahi R; Grossman A; Vitek P; Sundin A; Plöckinger U; ;
    Neuroendocrinology; 2009; 90(2):184-9. PubMed ID: 19713709
    [No Abstract]   [Full Text] [Related]  

  • 55. Endocrine tumours of the gastrointestinal tract. Somatostatin receptors as tools for diagnosis and therapy: molecular aspects.
    Guillermet-Guibert J; Lahlou H; Pyronnet S; Bousquet C; Susini C
    Best Pract Res Clin Gastroenterol; 2005 Aug; 19(4):535-51. PubMed ID: 16183526
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical endocrinology and metabolism. The somatostatin neuroendocrine system: physiology and clinical relevance in gastrointestinal and pancreatic disorders.
    Low MJ
    Best Pract Res Clin Endocrinol Metab; 2004 Dec; 18(4):607-22. PubMed ID: 15533778
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues.
    Rolleman EJ; Melis M; Valkema R; Boerman OC; Krenning EP; de Jong M
    Eur J Nucl Med Mol Imaging; 2010 May; 37(5):1018-31. PubMed ID: 19915842
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The history of somatostatin analogs.
    Pless J
    J Endocrinol Invest; 2005; 28(11 Suppl International):1-4. PubMed ID: 16625837
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Somatostatin receptor targeting for tumor imaging and therapy.
    Grötzinger C; Wiedenmann B
    Ann N Y Acad Sci; 2004 Apr; 1014():258-64. PubMed ID: 15153442
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention.
    Vegt E; de Jong M; Wetzels JF; Masereeuw R; Melis M; Oyen WJ; Gotthardt M; Boerman OC
    J Nucl Med; 2010 Jul; 51(7):1049-58. PubMed ID: 20554737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.